CompletedPhase 3NCT01557400

Study of Ataluren for Previously Treated Participants With Nonsense Mutation Duchenne/Becker Muscular Dystrophy (nmDBMD) in Europe, Israel, Australia, and Canada

Studying Becker muscular dystrophy

Last synced from ClinicalTrials.gov May 20, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: PTC Therapeutics
Principal Investigator: Edward O'Mara, MD, MD
PTC Therapeutics
Intervention: Ataluren(drug)
Enrollment: 94 enrolled
Eligibility: MALE
Timeline: 2012 – 2018

Study locations (21)

Royal Children's Hospital, Parkville, Melbourne, Australia
Institute For Neuromuscular Research, The Children's Hospital at Westmead, Westmead, Australia
University Hospital KU Leuven, Leuven, Belgium
Alberta Children's Hospital, Calgary, Alberta, Canada
British Columbia Children's Hospital, Vancouver, British Columbia, Canada
Children's Hospital of Western Ontario, London, Ontario, Canada
Hôpital d'Enfants CHU Timone, Marseille, France
Laboratoire d'Exploration Fonctionnelles, Nantes, France
Groupe Hospitalier La Pitie-Salpetriere, Paris, France
University of Essen - Clinic for Children, Essen, Germany
University Hospital, Freiburg im Breisgau, Germany
Hadassah Medical Center, Hebrew University Hospital, Jerusalem, Israel
Ospedale Maggiore Policlinico in Milan, Milan, Italy
Ospedale Pediatrico Bambino Gesu, Rome, Italy
U.O. Complessa di Neuropsichiatria Infantile, Rome, Italy
+6 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01557400 on ClinicalTrials.gov

Other trials for Becker muscular dystrophy

Additional recruiting or active studies for the same condition.

See all trials for Becker muscular dystrophy →

← Back to all trials